Thursday Aug 21
Supernus Pharmaceuticals Announces Paragraph IV Anda Filing for Trokendi XR
Supernus Pharmaceuticals, Inc. today announced that on August 20, 2014, the Company received a Paragraph IV Notice Letter from Actavis Laboratories FL, Inc. advising Supernus of the filing by Actavis of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules.
Supernus to Attend FBR HealthCare Conference in September
Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company, today announced that the Company's management will be hosting investor meetings during the FBR Healthcare Conference.
Medical News Today
Combination weight loss drugs hard to tolerate, but efficacious
Soon-to-be-available combination medication may be a viable option for obese Australians seeking to lose weight and maintain the loss, but only if they can manage its adverse effects, according to research published in the Medical Journal of Australia .
The San Diego Union-Tribune
Should a pharmaceutical sales rep be allowed to tell a doctor that Topamax, a drug approved to treat seizures and prevent migraine headaches, might also help combat alcohol dependence? Or suggest the epilepsy drug Neurontin could also help treat bipolar disorders or insomnia? Or offer data showing that any number of other drugs could have uses ... (more)
The Upsher-Smith Laboratories Galaxy??? Portfolio Of Antiepileptic Drugs Now Available
The current Upsher-Smith Galaxy Portfolio includes seven frequently prescribed AEDs which represent more than one out of every three prescriptions written for seizure disorders.1 The launch of the Upsher-Smith Galaxy demonstrates the company's commitment to simplifying access to effective treatments and reducing healthcare costs.